Patient Treatment Restarted in Ph 2 INVINCIBLE-4 Study of Neoadjuvant INT230-6 in TNBC Patients July 21, 2026
Ph 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors published in the JCO July 21, 2026
Positive Updated Ph 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma Announced July 21, 2026
Encouraging Preliminary Data from Ongoing Ph 2 Study of BPM31510 in Newly Diagnosed GBM Reported July 21, 2026
Jaypirca (pirtobrutinib) recommended by CHMP for approval in the EU for adults with CLL across all lines of therapy July 21, 2026
FDA Provides Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition July 21, 2026
FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors July 21, 2026
